CY1124669T1 - ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY - Google Patents
ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOYInfo
- Publication number
- CY1124669T1 CY1124669T1 CY20211100665T CY211100665T CY1124669T1 CY 1124669 T1 CY1124669 T1 CY 1124669T1 CY 20211100665 T CY20211100665 T CY 20211100665T CY 211100665 T CY211100665 T CY 211100665T CY 1124669 T1 CY1124669 T1 CY 1124669T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyrido
- tetrahydro
- indolioy
- estrogen drugs
- estrogen
- Prior art date
Links
- 229940046836 anti-estrogen Drugs 0.000 title 1
- 230000001833 anti-estrogenic effect Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000328 estrogen antagonist Substances 0.000 title 1
- UIXYIRXTZKEVDP-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-pyrido[3,4-b]indole Chemical class C1=CC=C2C3CCNCC3=NC2=C1 UIXYIRXTZKEVDP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235900P | 2015-10-01 | 2015-10-01 | |
| PCT/US2016/054549 WO2017059139A1 (en) | 2015-10-01 | 2016-09-29 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124669T1 true CY1124669T1 (el) | 2022-07-22 |
Family
ID=58427985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100665T CY1124669T1 (el) | 2015-10-01 | 2021-07-22 | ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10292971B2 (OSRAM) |
| EP (2) | EP3912680A1 (OSRAM) |
| JP (3) | JP6776348B2 (OSRAM) |
| KR (2) | KR102710603B1 (OSRAM) |
| CN (2) | CN108366996B (OSRAM) |
| AU (4) | AU2016331065B2 (OSRAM) |
| BR (2) | BR112018006121B1 (OSRAM) |
| CA (1) | CA3000410A1 (OSRAM) |
| CL (1) | CL2018000827A1 (OSRAM) |
| CY (1) | CY1124669T1 (OSRAM) |
| DK (1) | DK3355884T3 (OSRAM) |
| ES (1) | ES2881398T3 (OSRAM) |
| HR (1) | HRP20211124T1 (OSRAM) |
| HU (1) | HUE055321T2 (OSRAM) |
| IL (3) | IL286518B2 (OSRAM) |
| LT (1) | LT3355884T (OSRAM) |
| MX (2) | MX382269B (OSRAM) |
| NZ (1) | NZ779654A (OSRAM) |
| PL (1) | PL3355884T3 (OSRAM) |
| PT (1) | PT3355884T (OSRAM) |
| RS (1) | RS62133B1 (OSRAM) |
| RU (2) | RU2745742C1 (OSRAM) |
| SI (1) | SI3355884T1 (OSRAM) |
| SM (1) | SMT202100433T1 (OSRAM) |
| UA (1) | UA122346C2 (OSRAM) |
| WO (1) | WO2017059139A1 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2819448T3 (es) | 2014-12-18 | 2021-04-16 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos |
| RU2745742C1 (ru) | 2015-10-01 | 2021-03-31 | Олема Фармасьютикалз, Инк. | ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА |
| CN108495628B (zh) | 2015-12-09 | 2022-01-11 | 伊利诺伊大学评议会 | 苯并噻吩基选择性雌激素受体下调剂 |
| AU2017213614B2 (en) | 2016-02-05 | 2022-09-01 | Inventisbio Llc | Selective estrogen receptor degraders and uses thereof |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| WO2018019793A1 (en) * | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| WO2018049042A1 (en) * | 2016-09-07 | 2018-03-15 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| SMT201900602T1 (it) | 2016-10-24 | 2019-11-13 | Astrazeneca Ab | Derivato di 6,7,8,9-tetraidro-3h-pirazolo[4,3-f]isochinolina utile nel trattamento del cancro |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| EP3689873B1 (en) | 2017-01-30 | 2022-09-14 | Astrazeneca AB | Estrogen receptor modulators |
| WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| EA202092436A1 (ru) | 2018-05-14 | 2021-05-04 | Нувейшн Био Инк. | Противораковые соединения, нацеливающие на ядерные гормональные рецепторы |
| CR20230409A (es) | 2018-06-21 | 2023-09-25 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso (divisional expediente 2020-0621) |
| AU2018454987B2 (en) | 2018-12-24 | 2025-05-29 | InventisBio Co., Ltd. | Novel salts of selective estrogen receptor degraders |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN114302722A (zh) * | 2019-07-07 | 2022-04-08 | 奥列马制药公司 | 雌激素受体拮抗剂方案 |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2021178846A1 (en) | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| CN120267673A (zh) | 2020-04-24 | 2025-07-08 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的剂量方案 |
| KR20230005270A (ko) | 2020-04-24 | 2023-01-09 | 아스트라제네카 아베 | 약학적 제형 |
| US11848549B2 (en) * | 2020-09-15 | 2023-12-19 | Easy Solar Products, Inc. | Junction box with flashing for a tile surface |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| US20250049768A1 (en) * | 2021-07-08 | 2025-02-13 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| KR20250068623A (ko) | 2022-08-11 | 2025-05-16 | 이벡스타 바이오 | 암 치료용 화합물 |
| EP4573091A1 (en) | 2022-08-19 | 2025-06-25 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CA3262231A1 (en) | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP4573092A1 (en) | 2022-08-19 | 2025-06-25 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| KR20250095627A (ko) * | 2022-10-05 | 2025-06-26 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체-매개 장애의 치료 방법 |
| IL321349A (en) * | 2022-12-09 | 2025-08-01 | Olema Pharmaceuticals Inc | Dosage forms of estrogen receptor antagonists |
| WO2025106890A1 (en) * | 2023-11-17 | 2025-05-22 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2025168601A1 (en) | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| ES2204932T3 (es) * | 1994-09-12 | 2004-05-01 | Eli Lilly And Company Limited | Moduladores serotonergicos. |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6583170B1 (en) | 1998-05-15 | 2003-06-24 | Wyeth | 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
| WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
| AU2001271781A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| WO2002003986A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating breast disorders |
| CN1450913A (zh) | 2000-07-06 | 2003-10-22 | 惠氏公司 | 二膦酸酯、雌激素药物以及任选雌激素的联合应用 |
| AU2001271785A1 (en) | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Combinations of statins, estrogenic agents and optionally estrogens |
| AU2001271782A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted insole compounds for treating excessive intraocular pressure |
| JP2004502734A (ja) | 2000-07-06 | 2004-01-29 | ワイス | 一酸化窒素シンターゼ活性の増強方法 |
| EP1990051A1 (en) | 2000-07-06 | 2008-11-12 | Wyeth | Combinations of SSRI and estrogenic agents |
| EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| PT1318837E (pt) | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
| EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| JP2005528320A (ja) | 2001-08-11 | 2005-09-22 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 選択的なエストロゲン受容体モジュレーター |
| EP1720862A1 (en) | 2004-02-03 | 2006-11-15 | Eli Lilly And Company | Kinase inhibitors |
| EA201200555A1 (ru) * | 2004-03-15 | 2013-01-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Производные карболина, полезные в ингибировании ангиогенеза |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EP1846397A1 (en) | 2005-01-21 | 2007-10-24 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors |
| RU58668U1 (ru) | 2006-06-05 | 2006-11-27 | Открытое акционерное общество "Нижегородский машиностроительный завод" | Водогрейный котел |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| ES2826950T3 (es) | 2009-05-27 | 2021-05-19 | Ptc Therapeutics Inc | Métodos para tratar cáncer y afecciones no neoplásicas |
| WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| CA2800673A1 (en) | 2010-06-10 | 2011-12-15 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| EA029559B1 (ru) * | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
| CN104169266A (zh) | 2011-12-16 | 2014-11-26 | 奥乐玛药物股份有限公司 | 新的苯并吡喃化合物、其组合物和用途 |
| UY35590A (es) * | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| KR20160021277A (ko) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| KR20170087463A (ko) * | 2014-10-23 | 2017-07-28 | 오이 엠티지-멜트론 리미티드. | 위험 지역을 위한 조명 장치 |
| WO2016069932A1 (en) * | 2014-10-31 | 2016-05-06 | Karsten Manufacturing Corporation | Grooves of golf club heads and methods to manufacture grooves of golf club heads |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| WO2016097073A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| ES2819448T3 (es) | 2014-12-18 | 2021-04-16 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| RU2745742C1 (ru) | 2015-10-01 | 2021-03-31 | Олема Фармасьютикалз, Инк. | ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| EP3472159A1 (en) | 2016-06-16 | 2019-04-24 | F. Hoffmann-La Roche AG | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| SMT201900602T1 (it) | 2016-10-24 | 2019-11-13 | Astrazeneca Ab | Derivato di 6,7,8,9-tetraidro-3h-pirazolo[4,3-f]isochinolina utile nel trattamento del cancro |
| JP7085056B2 (ja) | 2018-07-12 | 2022-06-15 | イーライ リリー アンド カンパニー | 選択的エストロゲン受容体分解剤 |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2016
- 2016-09-29 RU RU2018115696A patent/RU2745742C1/ru active
- 2016-09-29 SM SM20210433T patent/SMT202100433T1/it unknown
- 2016-09-29 PL PL16852640T patent/PL3355884T3/pl unknown
- 2016-09-29 JP JP2018516524A patent/JP6776348B2/ja active Active
- 2016-09-29 ES ES16852640T patent/ES2881398T3/es active Active
- 2016-09-29 MX MX2018003929A patent/MX382269B/es unknown
- 2016-09-29 SI SI201631280T patent/SI3355884T1/sl unknown
- 2016-09-29 RU RU2021107754A patent/RU2021107754A/ru unknown
- 2016-09-29 CN CN201680067297.0A patent/CN108366996B/zh active Active
- 2016-09-29 US US15/764,988 patent/US10292971B2/en active Active
- 2016-09-29 LT LTEP16852640.8T patent/LT3355884T/lt unknown
- 2016-09-29 BR BR112018006121-2A patent/BR112018006121B1/pt active IP Right Grant
- 2016-09-29 KR KR1020187011902A patent/KR102710603B1/ko active Active
- 2016-09-29 WO PCT/US2016/054549 patent/WO2017059139A1/en not_active Ceased
- 2016-09-29 EP EP21164199.8A patent/EP3912680A1/en active Pending
- 2016-09-29 AU AU2016331065A patent/AU2016331065B2/en active Active
- 2016-09-29 HU HUE16852640A patent/HUE055321T2/hu unknown
- 2016-09-29 HR HRP20211124TT patent/HRP20211124T1/hr unknown
- 2016-09-29 NZ NZ779654A patent/NZ779654A/en unknown
- 2016-09-29 CA CA3000410A patent/CA3000410A1/en active Pending
- 2016-09-29 EP EP16852640.8A patent/EP3355884B1/en active Active
- 2016-09-29 IL IL286518A patent/IL286518B2/en unknown
- 2016-09-29 IL IL310489A patent/IL310489A/en unknown
- 2016-09-29 DK DK16852640.8T patent/DK3355884T3/da active
- 2016-09-29 RS RS20210924A patent/RS62133B1/sr unknown
- 2016-09-29 KR KR1020247031670A patent/KR20240142622A/ko active Pending
- 2016-09-29 BR BR122023020677-0A patent/BR122023020677A2/pt not_active Application Discontinuation
- 2016-09-29 CN CN202110308336.4A patent/CN113248494A/zh active Pending
- 2016-09-29 PT PT168526408T patent/PT3355884T/pt unknown
- 2016-09-29 UA UAA201804591A patent/UA122346C2/uk unknown
-
2018
- 2018-03-26 IL IL258363A patent/IL258363B/en unknown
- 2018-03-28 MX MX2021005214A patent/MX2021005214A/es unknown
- 2018-03-29 CL CL2018000827A patent/CL2018000827A1/es unknown
-
2019
- 2019-04-23 US US16/391,686 patent/US10624878B2/en active Active
-
2020
- 2020-04-17 US US16/852,272 patent/US11229630B2/en active Active
- 2020-10-07 JP JP2020169604A patent/JP7277424B2/ja active Active
-
2021
- 2021-07-22 AU AU2021206861A patent/AU2021206861B2/en active Active
- 2021-07-22 CY CY20211100665T patent/CY1124669T1/el unknown
- 2021-12-06 US US17/542,908 patent/US11672785B2/en active Active
-
2023
- 2023-04-28 AU AU2023202620A patent/AU2023202620B2/en active Active
- 2023-05-02 US US18/142,068 patent/US20240226073A9/en active Pending
- 2023-05-08 JP JP2023076673A patent/JP7650316B2/ja active Active
-
2025
- 2025-05-15 AU AU2025203540A patent/AU2025203540A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124669T1 (el) | ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| EA201791239A8 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| AU2015336400A8 (en) | Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof | |
| MX389354B (es) | Macrociclos peptidomimeticos y formulaciones de los mismos. | |
| WO2016028391A3 (en) | Spiropyrrolidines as mdm2 inhibitors | |
| CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
| CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| CY1124527T1 (el) | Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
| MY182008A (en) | Pharmaceutical formulations | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| EA201891289A1 (ru) | Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона | |
| MX351180B (es) | Composicion farmaceutica que comprende derivados de piridona. | |
| ECSP18023544A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| EA038580B9 (ru) | Агонист fxr, представляющий собой производное стероидов |